Annovis BioFRA:07X -0.47%32 EBIT per Share is €-1.48 as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,172 Biotechnology companies, Annovis Bio ranks better than 60.49% on this metric.
Annovis Bio's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.56.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.48.
During the past 3 years, the average EBIT per Share Growth Rate was 22.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Annovis Bio's EBIT per Share or its related term are showing as below:
FRA:07X'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -177 Med: -78.35 Max: 22.7
Current: 22.7
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Annovis Bio was 22.70% per year. The lowest was -177.00% per year. And the median was -78.35% per year.
FRA:07X's 3-Year EBIT Growth Rate is ranked better than 60.49% of 1172
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:07X: 22.70
Annovis Bio's EBIT for the
three
months ended in Mar. 2026 was €-15.58 Mil.
Annovis Bio (FRA:07X) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Annovis Bio EBIT per Share Related Terms
Annovis Bio EBIT per Share Historical Data
* Premium members only.
The historical data trend for Annovis Bio's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annovis Bio (FRA:07X) has a EBIT per Share of €-1.48 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Annovis Bio and its competitors. According to the industry distribution chart, Annovis Bio ranks #463 out of 1172 companies in the Biotechnology industry, placing it in the top 39.5%.
Is Annovis Bio's EBIT per Share too high?
Annovis Bio's current EBIT per Share is €-1.48. Based on the distribution chart, Annovis Bio ranks #463 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's EBIT per Share compare to HYFT and EXOZ?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #463 out of 1172 companies for EBIT per Share. This puts Annovis Bio in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Annovis Bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current EBIT per Share is €-1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current EBIT per Share of €-1.48. The current EBIT per Share is €-1.48. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current EBIT per Share is €-1.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score
Get the complete analysis for FRA:07X
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:07X has been successfully added to your 
